Project Grant R01NS150625

The National Institute of Neurological Disorders and Stroke awarded Oregon Health & Science University $619,833 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to decode PARP7 marylation-ubiquitylation crosstalk in neuronal health and disease.

The research will identify neuronal PARP7 substrates and marylation sites using chemical-genetic proteomics; establish the enzymatic machinery (writers, extenders, and erasers) that controls marubylation, a novel dual modification where ubiquitylation occurs on marylated residues; and investigate how PARP7-dependent modifications regulate the stability and function of P300, a key transcriptional co-activator critical for neuronal gene expression. The work targets PARP7 as a therapeutic candidate for stroke recovery, leveraging preliminary evidence that neuron-specific PARP7 knockdown and small-molecule PARP7 inhibitors enhance neurological function.

Performance extends from August 15, 2026, through July 31, 2031, at Oregon Health & Science University in Portland, Oregon. The award is a Project Grant, the standard research assistance type under the NINDS extramural program, and follows peer review by technical panels and the National Advisory Neurological Disorders and Stroke Council.